“Food and Drug” records a clinical study of an innovative vibrant treatment for the genetic probionic acidity

The Food and Drug General Authority agreed to register a clinical study entitled “A Global Study from the Second -Termination of the Second, open to improve the dose to evaluate safety, dynamics and pharmaceutical mobility of biological treatment (MRNA -3927) in participants with propionic acidity. The study aims to explore an innovative research remedy based on MRNA to treat One of the rare genetic diseases that affects the metabolism of amino acids.

The treatment aims to enable the body to produce the required enzyme internally, to restore normal functional activity and reduce the accumulation of toxic organic acids, which is reflected in improving the patient’s white balance.

The authority emphasized that this approval comes within the framework of its commitment to supporting clinical studies and attracting the latest scientific innovations, especially in the field of rare diseases, through an effective and transparent organizational environment that contributes to accelerating access to promising treatments.

This step also falls within the targets of the health sector transformation program, one of the Kingdom’s 2030 vision programs, in making the Kingdom an advanced regional center in the fields of research, development and health innovation.